EC warning over antimicrobial resistance

31 May 1999

The European Commission's main scientific advisory committee, the CDS,has noted serious concern over growing risks for human health resulting from antimicrobial resistance, and has called for immediate reduction in "inappropriate" use in human and veterinary medicine and in livestock and plant production.

The committee says that micro-organisms are becoming more and more resistant to known antimicrobial agents, including (and especially) antibiotics.

Of still more concern, say the CDS' 16 scientists, is that new antibacterial agents have not been introduced for 10 years, which is leading to growing difficulties in the treatment of pneumonia, tuberculosis and salmonellosis. They add that given that over 50% of antimicrobial agents are used in human drugs, doctors have an important role to play in reducing their use.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight